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ABSTRACT: SCN9A encodes the voltage-gated sodium channel Nav1.7, a protein highly expressed in 
pain-sensing neurons. Mutations in SCN9A cause three human pain disorders: bi-allelic loss of 
function mutations result in Channelopathy-associated Insensitivity to Pain (CIP), whereas 
activating mutations cause severe episodic pain in Paroxysmal Extreme Pain Disorder (PEPD) and 
Primary Erythermalgia (PE). To date, all mutations in SCN9A that cause a complete inability to 
experience pain are protein truncating and presumably lead to no protein being produced. Here, we 
describe the identification and functional characterization of two novel non-truncating mutations in 
families with CIP: a homozygously-inherited missense mutation found in a consanguineous Israeli 
Bedouin family (Nav1.7-R896Q) and a five amino acid in-frame deletion found in a sporadic 
compound heterozygote (Nav1.7-ΔR1370-L1374). Both of these mutations map to the pore region 
of the Nav1.7 sodium channel. Using transient transfection of PC12 cells we found a significant 
reduction in membrane localization of the mutant protein compared to the wild type. Furthermore, 
voltage clamp experiments of mutant-transfected HEK293 cells show a complete loss of function 
of the sodium channel, consistent with the absence of pain phenotype. In summary, this study has 
identified critical amino acids needed for the normal subcellular localization and function of 
Nav1.7.     ©2010 Wiley-Liss, Inc. 
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INTRODUCTION 
Pain is one of the most pervasive symptoms in clinical medicine; it occurs in a multitude of clinical conditions 
and is encountered by clinicians in every subspecialty. Yet treatment of pain remains challenging despite many 
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analgesic drugs and treatments with up to 50% of treated subjects receiving inadequate pain relief [Stewart et al., 
2003]. Thus there exists a significant need to develop better therapies. In this paper we explore one method to 
achieve this goal: the analysis of gene mutations in humans with altered pain perception. 
Over the past several years, elucidation of the genetic defects underlying three monogenic pain disorders has 
provided important insights about an unexpected component of human pain [Yang et al., 2004; Fertleman et al., 
2006; Cox et al., 2006]. Channelopathy-associated Insensitivity to Pain (CIP) is a rare condition in which patients 
have no pain perception and anosmia, but are otherwise essentially normal (MIM# 243000). Recently, genetic 
studies in families demonstrating recessively inherited CIP have identified nonsense mutations that result in 
truncation of the voltage-gated sodium channel type IX α subunit (SCN9A), a 113.5-kb gene comprising 26 exons 
(MIM# 603415) [Cox et al., 2006; Goldberg et al., 2007; Ahmad et al., 2007; Nilsen et al., 2009]. The encoded 
sodium channel is composed of 1977 amino acids and is organized into 4 domains, each with 6 transmembrane 
segments [Klugbauer et al., 1995]. The SCNA family of sodium channels (SCN1A-SCN11A) evolved from an 
archetypal potassium channel by quadruplication, where four potassium subunits have to coalesce to form the 
functional potassium channel. SCN9A is predominantly expressed in the dorsal root ganglion (DRG) neurons and 
sympathetic ganglion neurons [Rush et al., 2006]. Functional studies, performed for only some mutations to date, 
have shown that CIP-associated mutations lead to a loss of function of Nav1.7 [Cox et al., 2006].  
Heterozygous mutations that cause changes of amino acids in Nav1.7 result in very different pain phenotypes; 
Primary Erythermalgia (PE; MIM# 133020) and Paroxysmal Extreme Pain Disorder (PEPD; MIM# 167400) 
[Yang et al., 2004; Fertleman et al., 2006]. The primary symptoms associated with PE are severe chronic burning 
pain sensations in the hands and feet. The missense mutations causing PE are gain of function mutations that 
predominantly enhance the activation of Nav1.7 [Cummins et al., 2004]. PEPD is characterized by severe burning 
rectal, ocular, and submandibular pain sensations.  Eight distinct Nav1.7 missense mutations were reported in 
diﬀerent PEPD families that are different from those associated with erythermalgia [Fertleman et al., 2006]. The 
PEPD mutations that have been functionally characterized cause depolarizing shifts in voltage-dependence of 
steady-state inactivation and cause incomplete inactivation of Nav1.7, leading to prolonged persistent currents.  
Recently, heterozygous missense mutations in SCN9A have been reported to cause febrile seizures, but without 
altered pain perception (MIM# 603415) [Singh et al, 2009]. These mutations are all in highly conserved amino 
acids and are postulated to alter the function of brain-expressed Nav1.7. Analysis of a knock-in mouse for one of 
the reported mutations (N641Y) showed homozygous mice to be significantly more susceptible to seizures [Singh 
et al, 2009], supporting the hypothesis that this mutation is disease-causing.  
Thus prior to this study, missense mutations were only reported as leading to either excess or paroxysmal pain, 
or febrile seizures. Here we report for the first time missense mutations in SCN9A that cause CIP and demonstrate 
that the amino acid changes result in loss of function of Nav1.7. 
 
MATERIALS AND METHODS 
Patients and pedigrees 
Bedouin Patients  
The patients belong to a consanguineous family, one father with 2 first degree cousin wives (Figure 1a). We 
studied three sisters of the same nuclear family. Two of the girls were the offspring of one wife and another patient 
was the daughter of the second wife to the same father. Their ages were 15, 5 and 3 years respectively. The 
pregnancy and delivery were normal. All presented with a history of indifference to pain in early childhood, e.g. 
pin pricks or falls, with recurrent trauma including skin burns, fracture of bones and amputation of toes which 
caused them little distress. All patients had old skin scars due to burns, frequent cuts and bruises. Deformities of 
the limbs due to osteomyelitis of the upper and lower limbs and old bone fractures were evident, including a 
fracture of the shoulder which was identified by local swelling in one patient and a tibial bone fracture which was 
noticed due to limping in another. Trauma of the oral region was frequent in all patients. The tips of the tongues 
were amputated due to recurrent biting. The patients extracted their teeth and suffered from recurrent bouts of 
mandibular osteomyelitis. On examination the children were able to feel fine touch and pin prick but were 
indifferent to painful stimuli caused by squeezing the Achilles tendon and finger tips. In addition, they showed a E1672  Sheynin et al. 
normal histamine flare response, sweated normally and had normal intelligence. Nerve conduction studies 
performed in 2 of the patients revealed normal motor conduction with borderline reduction in the medial plantar 
sensory action potential (SAP). Their corneal responses were reduced. The patients presented the clinical picture of 
CIP and had no features of other hereditary sensory neuropathies. Specifically, the phenotype differed from 
patients with Congenital Insensitivity to Pain with Anhydrosis (CIPA; MIM# 256800) in that all had normal 
cognitive development, lack of unexplained bouts of fever in infancy and early childhood, normal lacrimal product 
and sweat, and normal sympathetic skin responses. The study was approved by the Soroka Helsinki committee. 
See Supp. Methods for more information.  
 
Figure 1. Novel mutations identified in SCN9A. (a) Pedigree and haplotype around the SCN9A gene of the Israeli Bedouin 
family with the Nav1.7-R896Q mutation; (b) Pedigree for British singleton carrying the two mutations Nav1.7-ΔR1370-L1374 
and Nav1.7- I1493SfsX8; (c) Schematic representation of the Nav1.7 sodium channel and locations of the identified mutations. 
The plasma membrane is shown in grey; transmembrane segments are labelled 1-6; the extracellular linkers between 
transmembrane segments 5 and 6 form the channel pore. Note that the Nav1.7-R896Q and Nav1.7-ΔR1370-L1374 mutations 
both map to similar regions of the channel in domain (D) 2 and 3 respectively. 
British patient  
The first child of healthy, non-consanguineous parents was referred aged one year for investigation for 
insensitivity to pain. The only complication of pregnancy or delivery was maternal fever 5 days prior to delivery 
that was treated with antibiotics. Birth weight was 4.2 kg and there were no obstetric or neonatal problems. First 
concerns were raised at age 6 months when she would bite her fingers during teething, showing no distress with 
the consequent injury. She had failed to show any discomfort with earlier childhood vaccinations. Subsequent 
injuries, including abrasion of her feet when learning to walk with a push-along walker and ulceration of her 
tongue following biting, similarly resulted in no distress. Aged 4 years she sustained a fracture to a right  SCN9A Loss of Function Mutations     E1673 
 
metatarsal. The lack of pain response coupled with erythema initially resulted in misdiagnosis of cellulitis and 
there was a delay of weeks in radiographic assessment (Supp. Figure S1). Now aged 5 years she has been taught 
and reasoned with to no longer bite her fingers. She gets upset at the presence of blood but does not respond 
normally to painful events. She seems to have preservation of temperature perception. Autonomic function has 
been normal including normal sweat production, pupillary reflexes, temperature control, bladder and bowel 
function. Histamine flare test was normal. Cognitive development has been normal. On examination at one year 
there were scars from bites on her fingers, ulceration of her tongue and scarring from injury on her toes. Deep 
tendon reflexes and light touch sensation were normal. Fungiform papillae of the tongue were present. Corneal 
reflexes were absent. Motor nerve conduction studies were normal, peroneal sensory action potential (SAP) was 
absent and median and ulnar SAPs reduced. Sural nerve biopsy was normal histologically.  Electron microscopy 
did reveal a few thinly myelinated axons surrounded by redundant Schwann cell basement membrane and although 
these could be interpreted to be in keeping with a demyelinating process, classical onion bulb formation was not 
present and there were no definitive abnormalities. A diagnosis of congenital insensitivity to pain was made and 
the normal development with absence of autonomic involvement led to consideration of SCN9A-associated pain 
insensitivity. 
Linkage analysis 
For the Bedouin family polymorphic markers for the region were developed using Tandem Repeats Finder 
[Gelfand et al., 2007] and PCR primers designed by the use of the "Primer3" web site 
(http://frodo.wi.mit.edu/primer3/).  PCR was performed on 50 ng DNA with the addition of 0.01 μCi α- [
32P] 
dCTP to enable visualization of the PCR products which were separated on 6% polyacrylamide gels and visualized 
by a Phosphor–Imager [Parvari et al., 1998].  
Mutation screening 
Genomic DNA was isolated from blood by standard methods. All coding exons and flanking splice sites of 
SCN9A were bi-directionally sequenced using either previously reported primers [Cox et al., 2006] or SCN9A ex 
15f: GAGATATTGAAAATTGATGAAAATGA and SCN9A ex 15r: CAAAATTTCGTTCTCTTTCCTG.  The 
c.2687G>A, c.4108_4122delCGATGGAAAAACCTG and c.4474delA mutations (NM_002977.3) were sought in 
260 ethnically matched control chromosomes by amplicon restriction analysis with BseDI  (Fermentas, Lithwania) 
(c.2687G>A) or bi-directional sequencing of genomic DNA. Nucleotide numbering reflects cDNA numbering 
with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to 
journal guidelines (www.hgvs.org/mutnomen). 
 
Verification of splicing 
Direct PCR amplification of reverse transcribed RNA from patient's lymphoblastoid cells 
RNA was extracted from lymphoblastoid cells of patient ip15 using the EZ-RNA II kit of Biological Industries 
(Israel) according to manufacturer instructions.  cDNA was synthesized from 5 microgram RNA by the Reverse –
iT 1
st strand synthesis kit of ABgene (Surrey, U.K.) with a decamer random primer. The PCR product confirming 
correct splicing was amplified using primers SCN9A-2310f: CCACCCAATGACTGAGGAAT and SCN9A-
2977r: GGTTGTTTGCATCAGGGTCT, PCR conditions were: 45 cycles of 95
o 1', 57
o 1', 72
o 1' and elongation of 
5' at 72
 o. The PCR product was directly sequenced. 
Minigene splicing assay 
A DNA fragment of 1037 bp containing the wild-type coding exon 15 along with 321 bp of upstream and 360 
bp of downstream intronic flanking regions was amplified from genomic DNA, sequenced and cloned into the 
NdeI site of the PTB minigene construct. The c.2687G>A mutation was created by PCR mutagenesis. Wild-type 
and mutant minigenes were transfected into HeLa cells using lipofectamine (Invitrogen). RNA was analysed by 
RT-PCR using primers specific for the minigene ALFA and BRA, followed by sequencing of the PCR products.  E1674  Sheynin et al. 
Construction of expression plasmids 
The wild-type SCN9A Î polio IRES Î DsRed2 construct (FLRED) and the SCN1B Î encephalomyocarditis 
virus (ECMV) IRES Î SCN2B Î polio IRES Î EGFP construct (JC5) were generated as previously described 
[Cox et al., 2006]. These bear either SCN9A and DsRed2 (FLRED) or SCN1B, SCN2B and EGFP (JC5) on the 
same vector expressed from the same promoter and the inclusion of DsRed2 and EGFP in these constructs helped 
in the identification of positively co-transfected cells when patch clamping. The Nav1.7-R896Q and Nav1.7 -
ΔR1370-L1374 mutations were introduced into FLREDN using the QuikChange XL Site-Directed Mutagenesis 
Kit (Stratagene) or by recombinant PCR respectively. The FLAG (DYKDDDDK) epitope was introduced into the 
above WT and mutant constructs into the domain I extracellular S1-S2 linker in frame between Pro 149 and Asp 
150, using recombinant PCR techniques. For the immunocytochemistry experiments, the polio IRES-DsRED2 
fragment was removed from the WT and mutant constructs so that only the Nav1.7 protein was expressed. All 
constructs were sequenced to verify the desired mutation and epitope and to ensure the lack of other introduced 
variations. 
 
Immunocytochemistry 
Rat pheochromocytoma cells (PC12) cultured in DMEM supplemented with 10% horse serum and 5% FCS, 
were transiently transfected with the WT or either of the 2 mutant constructs using lipofectamine 2000. The JC5 
construct was not co-transfected as endogenous beta subunits are present within PC12 cells. One day after 
transfection, the cells were fixed in ice-cold methanol for 5 mins and then permeabilized using acetone. Fixed cells 
were blocked with 3% BSA for 40 mins. Staining was carried out using the following antibodies: mouse 
monoclonal anti-Nav1.7 (1:250; Neuromab), mouse monoclonal anti-FLAG M2 (1:1000; Sigma), and rabbit 
polyclonal anti-Pan Cadherin (1:100; Sigma); all detected with appropriate Alexa Fluor secondary antibodies 
(1:250; Invitrogen). Slides were mounted using Prolong Gold antifade reagent with DAPI (Invitrogen) and 
examined using a Zeiss LSM510 META confocal laser-scanning inverted microscope (Carl Zeiss) equipped with 
an argon-krypton laser beam. At least 100 consecutive transfected cells per x3 coverslips were assessed for plasma 
membrane localization for each construct. To prevent bias the quantifying person was blinded against the nature of 
the analysed construct. Data was statistically analyzed using a Fisher’s two-tailed exact test. 
Electrophysiology 
HEK293A cells (QBiogene), cultured in DMEM supplemented with 5% FCS, were transiently transfected with 
plasmids expressing either WT or mutant Nav1.7 plus DsRed2 and/or SCN1B plus SCN2B plus EGFP using 
lipofectamine 2000. Whole-cell voltage clamp protocols were performed 2-3 days after transfection as previously 
described
 [Cox et al., 2006]. The bath solution contained (in mM): 3 KCl, 140 NaCl, 2 CaCl2, 1 MgCl2, 10 
HEPES, 1 glucose (pH7.4 with NaOH) and the patch pipette solution contained (in mM): 107 CsF, 10 NaCl, 1 
CaCl2, 2 MgCl2, 10 HEPES, 10 TEACl, 10 EGTA (pH 7.2 with CsOH). 
 
RESULTS 
Novel mutations identified in SCN9A 
Mapping and DNA sequence analysis in an Israeli Bedouin family 
Since the patients belong to the population of Bedouins in the south of Israel where congenital insensitivity to 
pain with anhydrosis (CIPA) is prevalent we firstly excluded linkage to the TrkA gene, assuming homozygosity in 
which the two alleles are identical by descent, by the use of microsatellite markers adjacent to the gene (data not 
shown). We next analyzed whether the patients presented homozygosity near the SCN9A gene, which was reported 
to be mutated in CIP patients [Cox et al., 2006; Goldberg et al., 2007; Ahmad et al., 2007; Nilsen et al., 2009]. 
Linkage to chromosome 2 (q23.3-q24.3), position 153,102,193–168,960,515  (NCBI Build 36.1 reference 
sequence) was confirmed by analysis of all family members for microsatellite markers in the region (Figure 1a). 
We searched for mutations in each of the coding exons and their intronic borders of this gene using DNA of 
patient ip3 and identified a single homozygous base substitution in coding exon 15 c.2687G>A resulting in amino  SCN9A Loss of Function Mutations     E1675 
 
acid change R896Q (reviewed but not shown). Arginine at position 896 is highly conserved, both evolutionary 
(Supp. Figure S2a) and in all sodium channels of the family (Supp. Figure S2b). This DNA change is not present 
in SNP or genomic databases. To exclude the possibility that the change is a population polymorphism, we 
determined its prevalence in healthy Bedouins of the same geographic region. The mutation eliminates a restriction 
site for the enzyme BseDI (Supp. Figure S3a). We analyzed 130 healthy Bedouins, using the elimination of a 
BseDI restriction site by the mutation, and found it was not present in any control individual (Supp. Figure S3b). 
However, since all 13 presently known mutations causing CIP truncate the protein, we verified that the substitution 
does not cause aberrant splicing. Firstly, bioinformatics analysis of the c.2687G>A coding exon 15 mutation using 
a battery of splice site/enhancer prediction algorithms (http://www.fruitfly.org/seq_tools/splice.html; 
http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home) showed that splicing control was unlikely to 
be disrupted by the mutation. Secondly, RNA was extracted from lymphoblastoid cells of patient ip15, and an RT-
PCR product was produced with primers fitting sequences in exons 14 and 16. The sequence of this product 
demonstrated that splicing was not altered (Supp. Figure S4a). Thirdly, we assessed the effect of the mutation on 
the control of splicing of exon 15 by a minigene assay. This showed that there was no difference between the wild-
type and mutant minigenes with both producing mRNA with normal inclusion of coding exon 15 (Supp. Figure 
S4b).  
DNA sequence analysis in the British patient 
Sequence analysis of SCN9A in the British proband revealed that she was a compound heterozygote for a de 
novo five amino acid in-frame deletion (Nav1.7 -ΔR1370-L1374) and a truncating mutation (Nav1.7-I1493SfsX8) 
(Figure 1b). Neither mutation is present in SNP or genomic databases or is predicted to disrupt splicing signals. 
Furthermore, these mutations were shown to be absent from 130 healthy Caucasian control individuals. 
Reduced cell surface expression of mutant channels 
All channelopathy-associated insensitivity to pain mutations reported to date cause premature truncation of the 
Nav1.7 sodium channel [Cox et al., 2006; Goldberg et al., 2007; Ahmad et al., 2007; Nilsen et al., 2009]. Similarly, 
one of the mutant alleles in the compound heterozygote (Nav1.7-I1493SfsX8) leads to truncation of the protein 
prior to domain 4 (Figure 1c), which would be predicted to cause a complete loss of function. However, the British 
five amino acid in-frame deletion (Nav1.7-ΔR1370-L1374) and the Bedouin missense mutation (Nav1.7-R896Q) 
are not expected to cause truncation but instead change the amino acid sequence in the S5-S6 extracellular loop of 
domains III and II of Nav1.7 respectively (Figure 1c). These loops form part of the sodium channel pore and both 
mutations are located just prior to the ion selectivity filter domain [Marban et al., 1998].  
  To study the effect of these mutations on the cellular localization of Nav1.7, FLAG-tagged SCN9A constructs 
were generated. The FLAG tag was inserted in the first extracellular loop in domain I of Nav1.7, similar to 
previous FLAG-tagging experiments performed for Nav1.5 [Makita et al., 2008; Liu et al., 2005]. Comparison of 
non-FLAG tagged and FLAG-tagged WT channels by patch clamping in HEK293 cells showed that epitope 
tagging did not affect the current densities or the gating properties of the sodium channel (Supp. Figure S5). 
Unfortunately, positively transfected cells could not be detected by immunostaining in a range of fixatives using a 
reliable anti-FLAG monoclonal antibody (data not shown). In HEK293 cells, we were also unable to see a 
convincing plasma membrane stain using a monoclonal anti-Nav1.7 antibody in cells transfected with the WT 
construct (data not shown). 
  We therefore switched to analysis of the FLAG-tagged SCN9A constructs in undifferentiated PC12 cells. Using 
the monoclonal anti-Nav1.7 antibody we could see an obvious intracellular staining in cells transfected with the 
wild-type construct (Figure 2a and Supp. Figure S6). Furthermore, in a proportion of cells we could see a faint but 
distinct ‘rim’ of staining which co-localized with the plasma membrane marker pan cadherin (Figure 2a). In 
contrast, cells transfected with the mutant channels Nav1.7-ΔR1370-L1374 and Nav1.7-R896Q typically showed 
no plasma membrane staining for Nav1.7, although a similar number of cells as in the wild-type transfected cells 
showed strong intracellular staining. This suggests that the mutations caused abnormal trafficking of the channels 
to the plasma membrane compared to WT (Figure 2a and Supp. Figure S6). However, this phenotype was not the 
same in every cell as a minority of mutant-transfected cells appeared to show some Nav1.7 staining at the plasma 
membrane. To quantify this result we counted at least 300 transfected cells over 3 coverslips for each construct 
(Figure 2b). This showed that there were significantly more WT-transfected cells with Nav1.7 plasma membrane 
staining than the number of mutant-transfected cells with Nav1.7 plasma membrane staining. This data suggests E1676  Sheynin et al. 
that both the missense and in-frame deletion pore mutations hamper the surface expression of Nav1.7, and may 
explain the reason for the loss of pain phenotype seen in these patients. 
 
Figure 2. (a) Immunostaining of PC12 cells expressing the Nav1.7 sodium channel. From left to right the staining is as follows: 
anti-Nav1.7, anti-pan cadherin, merged image (with DAPI in blue). The WT Nav1.7 shows a faint but distinct ‘rim’ which 
colocalizes with the plasma membrane marker pan cadherin. Both the missense (Nav1.7-R896Q) and the in-frame deletion 
(Nav1.7-ΔR1370-L1374) typically do not show this rim effect. For each transfection experiment a representative cell is shown, 
with the Z slice chosen as the one with the most plasma membrane staining according to the anti-pan cadherin marker. 
Untransfected cells showed some golgi-localized staining, but never staining at the plasma membrane.  (b) For each Nav1.7 
construct, at least 300 cells were assessed for plasma membrane staining of Nav1.7. There were significantly more transfected 
cells with Nav1.7 staining at the plasma membrane for the WT transfections compared to each of the mutants (* indicates 
statistically significant result). 
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Figure 3. Electrophysiological 
characterisation of HEK293 
cells transiently transfected with 
wild-type and mutant SCN9A. 
(A) Phase contrast, EGFP and 
DsRed2 fluorescence of 
HEK293 cells transiently co-
transfected with plasmids 
expressing SCN9A+DsRed2 and 
SCN1B+SCN2B+EGFP under a 
CMV promoter. Note that in the 
phase contrast with the patch 
pipette one of the fluorescently 
positive cells is missing as it 
was used in the previous patch 
experiment.  (B) Current 
responses to 50 ms voltage 
steps in 5 mV increments 
between -110 and +60 mV from 
a holding potential of -100 mV, 
in a whole cell voltage clamp 
recording applied at ~0.5 Hz for 
cells co-expressing either WT 
or mutant NaV1.7 (as indicated) 
with the β-subunits, identified 
by their fluorescence as shown 
in (A). The inset shows the 
voltage pulse protocol. (C) 
Current-voltage relationship of 
peak currents as shown in (B) 
normalised for cell size 
(pA/pF).   
NaV1.7+NaVβ1+NaVβ2 (n=5), 
 NaV1.7-ΔR1370-
L1374+NaVβ1+NaVβ2 (n=5),   
NaV1.7-R896Q+NaVβ1+NaVβ2 
(n=7),   NaVβ1+NaVβ2 only 
(n=5). WT data was fitted with 
a Boltzmann equation y = 
(A2+(A1-A2)/(1+exp((V0.5-
x)/k)(x-Vrev), where V0.5 = -33 
mV, k= 2 mV Vrev= 65 mV. 
 
 
Mutations cause a complete loss of function of Nav1.7 
Given that plasma membrane staining was occasionally seen when the mutant channels were overexpressed, we 
decided to investigate how the mutations affected the biophysical properties of the sodium channel. To do this, 
plasmids bearing either WT SCN9A or the mutant sequences were co-expressed in HEK293A cells with the 
auxiliary sodium channel β1 and β2 subunits (encoded by SCN1B and SCN2B). Whole cell voltage clamp 
recordings from cells co-expressing wild-type Nav1.7 with the β1β2 subunits, revealed a voltage-gated Na
+ current 
with a peak amplitude of -685 ± 134 pA/pF at -20 mV (n=5), compared with a background current of -13 ± 2 
pA/pF (n=5) in cells transfected with the β1β2 construct alone (p=0.001 for wild-type Nav1.7 vs control) (Figure 3). 
The voltage dependence of activation of Nav1.7 could be described by a Boltzmann function, with half maximum 
activation (V0.5) of -33± 2 mV, k = 2 ± 1 mV and a reversal potential (Vrev) of +65 ± 4 mV (n=5). Voltage 
dependent inactivation could also be described by a Boltzmann function with half maximal inactivation at -74 ± 2 
mV and k = 4.3 ± 0.6 mV (n=5) (Supp. Figure S5). These properties are similar to those described previously for 
Nav1.7 current [Klugbauer et al., 1995; Cummins et al, 2004; Herzog et al., 2003]. In contrast, cells co-transfected E1678  Sheynin et al. 
with either of the mutated Nav1.7 subunits plus β1β2, exhibited currents that were not significantly different from 
those recorded from control cells (Figure 3). The mean peak currents at -20 mV were: -11 ± 3 pA/pF (n=7, p>0.6 
vs control) and -13 ± 5 pA/pF (n=5, p>0.9 vs control) for Nav1.7-R896Q and Nav1.7-ΔR1370-L1374 respectively. 
Hence, the two mutations completely abolish the function of the voltage-gated sodium channel, which is consistent 
with the complete insensitivity to pain phenotype seen in affected individuals from these two families. 
 
DISCUSSION 
The ability to treat pain will hopefully improve upon our understanding of its molecular basis. The Nav1.7 
voltage-gated sodium channel is a major and non-redundant part of pain perception and the identification of 
mutations that change its function holds the potential to contribute to pain relief. In particular, identification of the 
structural regions that are critical for the normal function of Nav1.7 is important as these regions could be targeted 
for the development of novel analgesics. However, all the CIP mutations reported to date have been truncating 
mutations, thus failing to reveal specific amino acids that are critical for normal function of Nav1.7. Here we 
present the first CIP missense and in-frame deletions in SCN9A. These null mutations highlight specific 
functionally significant amino acids, both being in the same functional domain of the Nav1.7 protein. 
Previously reported missense mutations in Nav1.7 have been associated with PE, PEPD or febrile seizures and 
are mostly located to cytoplasmic linkers of the sodium channel, with some PE causing mutations in 
transmembrane domains. While it is not clear how and why these different gain-of-function mutations result in 
distinct disorders, it seems that PE causing mutations typically cause a hyperpolarizing shift in the voltage 
dependence of channel activation and a delay in deactivation of active channels upon return to non-activating 
membrane voltages. Both would increase the Nav1.7 currents at small deviations from the resting potential and the 
likelihood of action potential initiation, presumably sensitizing the neurons expressing these channels to small 
depolarising stimuli. PEPD causing mutations by contrast typically result in depolarizing shifts in the voltage 
dependence of fast inactivation, which is also seen in some PE-causing mutations, but importantly also rendering 
this process incomplete, thus resulting in persistent inward currents again leaving nociceptive neurons expressing 
these channels hyperexcitable [Drenth and Waxman, 2007]. More recently a mutation (Nav1.7-A1632E) which 
results in hyperpolarising shift in the voltage dependence of activation concomitantly with partial fast inactivation 
has been described in a patient with symptoms of both PE and PEPD [Estacion et al., 2008]. 
The missense mutation and in-frame deletion described here both map to the central sodium influx pore region 
of Nav1.7. The pore is formed by asymmetric loops (P segments) contributed by each of the four domains of the 
protein. The P segments are accessible only from the extracellular surface, with each undergoing a hairpin turn in 
the permeation pathway such that amino acids on both sides of the putative selectivity ﬁlter line the outer mouth of 
the pore. Evolutionary conservation of the pore helix motif from bacterial potassium channels to mammalian 
sodium channels identiﬁes this structure as a critical feature in the architecture of ion selective pores [Yamagishi et 
al., 2001]. The mutations we describe both cause a significant reduction in the number of cells with plasma 
membrane staining of Nav1.7 by immunocytochemistry in transfected PC12 cells. This is similar to what happens 
for specific mutations in SCN5A, where the mutant channel becomes retained in the endoplasmic reticulum (ER) 
[Liu et al., 2005; Baroudi et al., 2001]. It is therefore conceivable that the SCN9A mutations described here also 
cause misfolding of the channel which leads to ER retention and hence defective cell surface localization of 
Nav1.7. However, as a minority of cells overexpressing the mutant protein appeared to show some plasma 
membrane staining, it seems reasonable to hypothesize that even if some mutant protein can make it to the 
membrane, insufficient current densities are reached, possibly due to malfolding of the channel pore. Whichever is 
the principal mutational mechanism, the result is a non-functional sodium channel causing congenital insensitivity 
to pain in the patients. 
In summary, we have identified two novel non-truncating mutations in SCN9A which further expands the 
spectrum of mutations seen in Channelopathy-associated Insensitivity to Pain. The location of the mutations within 
the channel pore highlights the importance of this structure to channel function and shows how the highly 
regulated folding of this region can be disrupted by the alteration of a single amino acid. For analgesic design it 
suggests further possibilities: design of a moiety that can bind to the Nav1.7 sodium pore; and discovery, and then 
inhibition, of the chaperone protein that correctly folds Nav1.7 prior to its trafficking to the membrane. 
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SUPPORTING INFORMATION 
 
 
Supp. Figure S1.Images of the painless compacted fracture suffered by the British patient.  SCN9A Loss of Function Mutations     E1681 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supp. Figure S2. Conservation of arginine at position 896. (a) Evolutionary conservation; (b) conservation 
across Na channel family members.  E1682  Sheynin et al. 
 
 
 
Supp. Figure S3. Analysis of the prevalence of the mutation in the patients' population. (a) Schematic demonstration of the 
analysis, a 693bp PCR product is cut by the restriction enzyme BseDI; (b) PCR products after BseDI restriction separated on a 
2% agarose gel. DNA molecular weight marker is shown in the far right lane. 
  SCN9A Loss of Function Mutations     E1683 
 
 
Supp. Figure S4. The c.2687G>A mutation does not alter splicing.  (a) Partial sequence chromatogram of the RT-PCR 
spanning exons 14 to 16. The mutation is shown by an arrow. The nucleotides at the normal splicing sites at both sides of exon 
15 are boxed. (b) Minigene assay to investigate whether the c.2687G>A mutation disrupts splicing control of SCN9A. The 
reporter gene is composed of α-globin (black boxes) and fibronectin exons (shaded boxes). WT or mutant coding exon 15 along 
with upstream and downstream intronic sequence were cloned into the NdeI site of the PTB minigene construct followed by 
transfection into HeLa cells. RT-PCR analysis shows that in the wild-type context (Lane 1) a PCR product of 594 bp was 
amplified which represented normal inclusion of exon 15 in the mature transcript. The minigene carrying the mutation behaved 
in an identical manner (Lane 2).  E1684  Sheynin et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supp. Figure S5. Voltage dependent activation and inactivation of wild-type and FLAG-tagged NaV1.7 
channels. (A) (left) Current responses to 50 ms voltage steps in 5 mV increments between -110 and +60 mV 
from a holding potential of -100 mV, in a whole cell voltage clamp recording applied at 0.5 Hz for a cell co-
expressing FLAG-tagged NaV1.7 with the β-subunits. The inset shows the voltage pulse protocol. (right) 
Current-voltage relationship of peak currents as shown on the left normalised for cell size (pA/pF).   
NaV1.7+NaVβ1+NaVβ2 (n=5),   FLAG-tagged NaV1.7+NaVβ1+NaVβ2 (n=5). The data was fitted with a 
Boltzmann equation y = (A2+(A1-A2)/(1+exp((V0.5-x)/k)(x-Vrev). There was no significant difference between 
currents from wild-type and FLAG-tagged NaV1.7-expressing cells, with  V0.5 = -33±1 mV and -33±2 mV; k= 
2±1 mV and 3±1 mV; and Vrev= 65±4 mV and 67±4 mV respectively. The peak current for FLAG-tagged 
NaV1.7 at -20 mV was 591±115 pA/pF which was not significantly different from wild-type expressing cells. (B) 
(left) Current responses of a FLAG-tagged NaV1.7+NaVβ1+NaVβ2 expressing cell in whole cell voltage clamp to 
a 50 ms test pulse to a potential of -10 mV applied immediately after 500 ms conditioning voltage steps to 
potentials from -120 to 0 mV (at 5 mV increments). The inset shows the voltage pulse protocol applied at 0.5 
Hz.  (right) Voltage dependence of the steady-state inactivation assessed as on the left for    
NaV1.7+NaVβ1+NaVβ2 (n=5),   FLAG-tagged NaV1.7+NaVβ1+NaVβ2 (n=5). The data was fitted with a 
Boltzmann equation y = (A1-A2)/(1+exp(x-V0.5)/k)) + A2. There was no significant difference between currents 
from wild-type and FLAG-tagged NaV1.7-expressing cells, with V0.5 = -74±5 mV and 76±1 mV and k= 4±1 mV 
and 6±1 mV respectively.   SCN9A Loss of Function Mutations     E1685 
 
 
Supp. Figure S6.  Immunostaining of PC12 cells expressing the Nav1.7 sodium channel. From left to right the staining is as 
follows: anti-Nav1.7, anti-pan cadherin, merged image (with DAPI in blue). These low magnification images illustrate that 
there was equal transfection efficiency for each of the constructs. E1686  Sheynin et al. 
SUPP. METHODS 
Additional Bedouin family clinical data 
The patients did not have bouts of unexplained fever (but had fever during infections), they had no dysphagia or 
vomiting. They had tears during emotional upset and had normal sweating. All had good bladder control (the 
youngest patient has nocturnal enuresis).  One of the patients had a corneal abscess treated with parenteral 
antibiotics followed by tarsoraphy. According to the parents the children were indifferent to some flavours such as 
to an excess of salty food. (They appreciate food by vision). The patients were considered by their parents to have 
a well developed cognitive state, the elder one attended school. On examination the children were co-operative 
with well developed verbal skills and normal voices. They were oriented to place, time and to people. The ocular 
movements were normal, the pupils were round, equal and reacting to direct and consensual light with the presence 
but reduced corneal reflex and with lacrimation. The fundoscopic examinations were normal. Facial movements 
were normal. The tongues were normal with no fasciculation and with the presence of fungiform papillae. The 
uvulas were at the midline with intact gag reflex and swallowing. The tone was mildly reduced with normal bulk 
of muscles. The strength at both upper and lower limbs was 5/5. Deep tendon reflexes and plantar responses were 
normal. Cerebellar functions were normal. The gait and stance were normal. A mild laxity of joints was noticed. 
The motor conduction studies of the right peroneal and left tibial nerves showed normal distal latencies amplitudes 
and velocities. All patients had sweat in the armpits and on the palmar regions. There was no superficial peripheral 
nerve enlargement on palpation. 
 
The patients were tested by the following methods: Motor and sensory nerve conduction studies as well as the 
sympathetic skin responses were performed on a Keypoint machine (Medtronic, Copenhagen, Denmark) using 
standard methods.  
The motor nerve studies included the peroneal, tibial and median nerves. 
The sensory studies included the medial planar and median nerves. 
The sympathetic skin responses were recorded from the palms of hands.  
Heart rate variability was evaluated during resting and deep breath. 
Schirmer test was performed by applying film in the tarsal plate and measuring the length of wet film. 
Sweat test was performed by applying a scopolamine patch. 
Histamine test was performed by pin-pricking with histamine and measuring the flare responses.  
The results of the tests: The motor conduction studies of tibial, peroneal and median nerves showed normal 
distal latencies amplitudes and velocities. The sensory studies of the medial plantar nerves showed normal 
latencies amplitudes and velocities. Sympathetic skin responses of the median nerves recorded from the palm were 
normal in all patients to electrical stimulation of the palm. 
Sweat test, Schirmer test and Histamine test were all normal. 